This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 Sep 26;381(13):1284-1286.

doi: 10.1056/NEJMcibr1909386. Epub 2019 Sep 10.

HER2 and Breast Cancer - A Phenomenal Success Story

Daniel F Hayes¹

Affiliations

PMID: 31502769
DOI: 10.1056/NEJMcibr1909386

HER2 and Breast Cancer - A Phenomenal Success Story

Daniel F Hayes. N Engl J Med. 2019.

. 2019 Sep 26;381(13):1284-1286.

doi: 10.1056/NEJMcibr1909386. Epub 2019 Sep 10.

Author

Daniel F Hayes¹

Affiliation

¹ From the University of Michigan Rogel Cancer Center, Ann Arbor.

PMID: 31502769
DOI: 10.1056/NEJMcibr1909386

No abstract available

PubMed Disclaimer

Comment in

Progress in the Treatment of Breast Cancer.
Konner M. Konner M. N Engl J Med. 2020 Jan 9;382(2):e4. doi: 10.1056/NEJMc1915045. N Engl J Med. 2020. PMID: 31914253 No abstract available.

Similar articles

Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.
[No authors listed] [No authors listed] Cancer Biol Ther. 2004 Jun;3(6):490. Cancer Biol Ther. 2004. PMID: 15717407 No abstract available.
The 2008 Fred Waldorf Stewart Award: Paul Peter Rosen, MD.
Rosenblum MK, Brogi E, Tan LK. Rosenblum MK, et al. Am J Surg Pathol. 2009 May;33(5):799-800. doi: 10.1097/PAS.0b013e31819b9173. Am J Surg Pathol. 2009. PMID: 19252431 No abstract available.
The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
Slamon DJ. Slamon DJ. Oncologist. 2004;9 Suppl 3:1-3. doi: 10.1634/theoncologist.9-suppl_3-1. Oncologist. 2004. PMID: 15163840 No abstract available.
Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A, Cañadas-Garre M, Sánchez-Pozo A, Calleja-Hernández MÁ. Madrid-Paredes A, et al. Breast Cancer Res Treat. 2015 Oct;153(3):493-505. doi: 10.1007/s10549-015-3578-x. Epub 2015 Sep 23. Breast Cancer Res Treat. 2015. PMID: 26400847 Review.
Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL. Subramaniam D, et al. Curr Cancer Drug Targets. 2015;14(9):775-93. doi: 10.2174/1568009614666141111104643. Curr Cancer Drug Targets. 2015. PMID: 25435079 Review.

See all similar articles

Cited by

Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.
Guerriero JL, Lin JR, Pastorello RG, Du Z, Chen YA, Townsend MG, Shimada K, Hughes ME, Ren S, Tayob N, Zheng K, Mei S, Patterson A, Taneja KL, Metzger O, Tolaney SM, Lin NU, Dillon DA, Schnitt SJ, Sorger PK, Mittendorf EA, Santagata S. Guerriero JL, et al. NPJ Breast Cancer. 2024 Jan 2;10(1):2. doi: 10.1038/s41523-023-00605-3. NPJ Breast Cancer. 2024. PMID: 38167908 Free PMC article.
Identifying clinical features and molecular characteristics of the endometrial clear cell carcinoma.
Cai Y, Han Q, Guo H. Cai Y, et al. Front Oncol. 2023 Nov 17;13:1286176. doi: 10.3389/fonc.2023.1286176. eCollection 2023. Front Oncol. 2023. PMID: 38045002 Free PMC article.
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.
Koirala N, Dey N, Aske J, De P. Koirala N, et al. Int J Mol Sci. 2022 Jun 11;23(12):6547. doi: 10.3390/ijms23126547. Int J Mol Sci. 2022. PMID: 35742993 Free PMC article. Review.
Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab.
Sharaf BM, Giddey AD, Alniss H, Al-Hroub HM, El-Awady R, Mousa M, Almehdi A, Soares NC, Semreen MH. Sharaf BM, et al. Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):79-93. doi: 10.21873/cgp.20305. Cancer Genomics Proteomics. 2022. PMID: 34949661 Free PMC article.
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.
Jørgensen JT, Winther H, Askaa J, Andresen L, Olsen D, Mollerup J. Jørgensen JT, et al. Front Oncol. 2021 Jul 23;11:676939. doi: 10.3389/fonc.2021.676939. eCollection 2021. Front Oncol. 2021. PMID: 34367962 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Personal name as subject

Actions
- Search in PubMed
- Add to Search
Actions
- Search in PubMed
- Add to Search
Actions
- Search in PubMed
- Add to Search

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal